SLN360
Silence Therapeutics
[]
silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting - 
MD MSC CPDS https://t.co/kePCRsvthW  https://t.co/t7oxnCDRg8  #cardiology  #AI #informatics #healthcare #innovation #entrepreneur RSS feeds